找回密碼
 To register

QQ登錄

只需一步,快速開始

掃一掃,訪問微社區(qū)

打印 上一主題 下一主題

Titlebook: Difficult Decisions in Thoracic Surgery; An Evidence-Based Ap Mark K. Ferguson Book 20112nd edition Springer-Verlag London Limited 2011 Gen

[復(fù)制鏈接]
樓主: 使委屈
21#
發(fā)表于 2025-3-25 05:34:31 | 只看該作者
Decision Making: The Patient’s Perspective counseling, patients score ‘D’ on knowledge tests and ‘F’ on their understanding of the probabilities of benefits and harms. Moreover, there is a mismatch between the benefits and harms that patients value most and the option that is chosen. Patients participate in decision making less than they pr
22#
發(fā)表于 2025-3-25 08:54:04 | 只看該作者
PET for Mediastinal Restaging of Patients with Non Small Cell Lung Cancer after Induction Therapyancer (NSCLC) continues to be a challenge. Identifying pathological N2 disease is of importance because it significantly affects outcomes and potential treatment strategies. More widespread utilization of endobronchial ultrasound techniques and refinements in fluorodeoxyglucose positron emission tom
23#
發(fā)表于 2025-3-25 15:41:08 | 只看該作者
Optimal Initial Pathologic Mediastinal Staging of Lung Cancer: EUS, EBUS, Mediastinoscopy, mediastinal lymph node staging is an important branch point in deciding therapy. The initial clinical evaluation of patients with suspected lung cancer includes a contrast CT scan of the chest and upper abdomen that provides staging information about the T descriptor and usually leads to a presump
24#
發(fā)表于 2025-3-25 18:36:58 | 只看該作者
VATS vs. Open Lobectomy for Early Stage Non-Small Cell Lung Cancer(American Joint Committee on Cancer [AJCC] stage I and II) non-small cell lung cancer (NSCLC).. Patients with untreated stage I NSCLC, albeit an early stage neoplasm, have a 5-year survival rate of less than 5%.. – . Radiation and chemotherapy (alone or in combination) offer little survival benefit.
25#
發(fā)表于 2025-3-25 21:28:20 | 只看該作者
26#
發(fā)表于 2025-3-26 00:31:15 | 只看該作者
27#
發(fā)表于 2025-3-26 05:42:29 | 只看該作者
Lobectomy After Induction Therapy for Stage IIIA NSCLC in the Presence of Persistent N2 Diseaseiverse clinical scenarios (Table 11.1).. For many of these N2 subsets the therapeutic options are well known and are accepted in the clinical practice.. Patients with potentially resectable N2 disease detected preoperatively usually undergo induction treatment (chemotherapy and/or chemoradiotherapy)
28#
發(fā)表于 2025-3-26 09:13:05 | 只看該作者
29#
發(fā)表于 2025-3-26 14:29:18 | 只看該作者
30#
發(fā)表于 2025-3-26 17:56:17 | 只看該作者
Optimal Therapy for Patients with Marginal Lung Function and Peripheral Stage I Lung Cancer lower the FEV1%, the higher the risk of developing NSCLC.. Due to the association between both diseases, COPD patients are frequently referred for lung resection for NSCLC. In this chapter we review recently published evidence regarding the best therapeutic option for stage I NSCLC patients with ma
 關(guān)于派博傳思  派博傳思旗下網(wǎng)站  友情鏈接
派博傳思介紹 公司地理位置 論文服務(wù)流程 影響因子官網(wǎng) 吾愛論文網(wǎng) 大講堂 北京大學(xué) Oxford Uni. Harvard Uni.
發(fā)展歷史沿革 期刊點評 投稿經(jīng)驗總結(jié) SCIENCEGARD IMPACTFACTOR 派博系數(shù) 清華大學(xué) Yale Uni. Stanford Uni.
QQ|Archiver|手機版|小黑屋| 派博傳思國際 ( 京公網(wǎng)安備110108008328) GMT+8, 2025-10-7 19:32
Copyright © 2001-2015 派博傳思   京公網(wǎng)安備110108008328 版權(quán)所有 All rights reserved
快速回復(fù) 返回頂部 返回列表
垦利县| 西盟| 襄樊市| 鹤庆县| 冀州市| 乌拉特后旗| 神池县| 达孜县| 长岭县| 和平区| 民勤县| 北海市| 昭通市| 威信县| 山阴县| 咸宁市| 辽源市| 阿坝| 巢湖市| 张家川| 张家界市| 比如县| 莱州市| 昔阳县| 邛崃市| 山西省| 延庆县| 赣榆县| 青州市| 寻甸| 正蓝旗| 连城县| 共和县| 太原市| 台中县| 遂平县| 琼海市| 同江市| 滕州市| 长汀县| 白城市|